Singapore markets closed

Straits Times Index
3,297.55
-26.98(-0.81%)
Nikkei
38,814.56
+94.06(+0.24%)
Hang Seng
17,941.78
-170.82(-0.94%)
FTSE 100
8,146.86
-16.81(-0.21%)
Bitcoin USD
66,603.59
+474.11(+0.72%)
CMC Crypto 200
1,382.19
-35.68(-2.52%)

SANA Jun 2024 10.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.1500

-0.0100

(-6.25%)

As of 03:00PM EDT. Market open.

GlobeNewswire
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice Additional proof-of-concept for the advancement of SC379, Sana’s pluripotent stem cell-derived glial progenitor cell product candidate SEATTLE, May 21, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today highlighted that Nature Biotechnology has published a paper titled “You
Simply Wall St.
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
GuruFocus.com
Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results
Aligns with Analyst Projections Amidst Strategic Clinical Advancements